Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment for haematological malignancy.
We report our recent experience with two cases of invasive pulmonary aspergillosis in patients who were both undergoing chemotherapy, one for acute myeloid leukaemia and the other for primary amyloidosis. Both patients had bad prognostic factors and were in very poor clinical condition, but both recovered from infection after a prolonged therapy with liposomal amphotericin B (AmBisome) without signs of toxicity.
Mele
L
L
Pagano
L
L
Equitani
F
F
Leone
G
G
D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use*; D000686:Amyloidosis / Q000150:complications; D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy*; D001231:Aspergillus flavus; D001232:Aspergillus fumigatus; D001927:Brain Diseases / Q000209:etiology*; D017809:Fatal Outcome; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy*; D008172:Lung Diseases, Fungal / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000935:Antifungal Agents; D000970:Antineoplastic Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B